Morphic Therapeutic
35 Gatehouse Drive A-2
Waltham
Massachusetts
02451
United States
Tel: 781-996-0955
Website: http://morphictx.com/
Email: info@morphictx.com
About Morphic Therapeutic
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.YEAR FOUNDED:
December 2015
LEADERSHIP:
CEO: Praveen Tipirneni, M.D.
Chief Development Officer: Alex Lugovskoy, Ph.D.
Vice President of Chemistry: Blaise Lippa, Ph.D.
Vice President of Finance and Operations: Robert Farrell, CPA
111 articles about Morphic Therapeutic
-
Morphic Therapeutic to Present at the Jefferies Virtual Healthcare Conference
5/28/2021
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to present at the Jefferies Virtual Healthcare Conference on June 4, 2021 at 9:00 AM ET.
-
Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results
4/29/2021
Presented positive preclinical data fromαvβ8program at AACR Annual Meeting demonstrating anti-tumor activity in checkpoint refractory cancer models
-
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of DirectorsOtello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term
4/28/2021
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its Board of Directors.
-
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting
4/12/2021
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the presentation of the first preclinical data from its αvβ8 integrin program at the 2021 American Association for Cancer Research (AACR) Annual Virtual Meeting.
-
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
3/3/2021
Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share.
-
Morphic Therapeutic Announces Proposed Public Offering
3/1/2021
Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering in which it intends to offer and sell $200.0 million of shares of its common stock.
-
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
3/1/2021
MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 integrin at three highest dose levels; demonstrates ability to saturate α4β7 receptor
-
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020
3/1/2021
Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, reported corporate highlights and financial results for the full year 2020.
-
Morphic Therapeutic to Host Analyst and Investor Call on March 1, 2021Call to discuss financial and operational results for fiscal year 2020 and MORF-057 interim data from SAD portion of ongoing MORF-057 Phase 1 clinical trial
2/22/2021
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the financial results and operational milestones for its fiscal year 2020, ended December 31, 2020.
-
Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference
2/16/2021
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to participate in a panel discussion on the gastrointestinal microbiome at the 41 st Annual Cowen Health Care Conference. The panel discussion will take place a
-
Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin ProgramNew program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets
1/5/2021
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the expansion of its research and development collaboration with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
12/30/2020
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET
-
Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors
12/4/2020
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W. Edwards, to its Board of Directors.
-
Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference
11/17/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to participate in the Jefferies Virtual London Healthcare Conference with a Company presentation at 2:55 PM ET on Wednesday, November 18, 2020. A live webcast of the company presentation will be avai
-
Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results
11/9/2020
Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021 Presented d ata at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057 Received $20 million from AbbVie exercising option to αvβ6 integrin inhibitor program
-
Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020
10/12/2020
Data validate physiologically relevant assay used inMORF-057 Phase 1 studies to measurereceptor occupancy of α4β7 integrin
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
9/23/2020
Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced that the first healthy volunteers have received MORF-057 in a phase 1 clinical trial designed to evaluate MORF-057’s safety and pharmacokinetic profile in addition to predictive pharmacodynamic signals.
-
Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit
9/21/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit. Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m. ET on Wednesday, September 23, 2020, as well as present a company
-
Morphic Announces Participation in Upcoming Investor Conferences
9/3/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences: Praveen Tipirneni, M.D., president and chief executive officer is scheduled to take part in a fireside chat at 8:40 am ET on Thursday, September 10 at the 2020 Wells Fargo Virtual Healthcare Conference The Mo